Brimondine/loteprednol etabonate - Ocugen

Drug Profile

Brimondine/loteprednol etabonate - Ocugen

Alternative Names: loteprednol etabonate/brimondine - Ocugen; OCU 310

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ocugen
  • Class Androstadienes; Eye disorder therapies; Imidazoles; Quinoxalines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 20 Mar 2018 Adverse events and efficacy data from a phase II trial in Dry eyes, which met its primary endpoint, released by Ocugen
  • 25 Sep 2017 Phase-II clinical trials in Dry eyes in USA (Topical)
  • 25 Sep 2017 Ocugen files an IND application with the US FDA for a proof of concept phase II trial for the treatment of Dry eyes before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top